Predicting immunotherapy success in chest cancers
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This study is for people with lung or esophageal cancer who will receive immunotherapy (drugs that help your immune system fight cancer). The researchers want to find markers in your blood and tumor that can predict how well the treatment will work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lung cancer or esophageal cancer and are ready to start immunotherapy with a PD-1 or PD-L1 drug.
- You are between 18 and 80 years old.
- You are able to do most of your daily activities without needing help (ECOG 0 or 1).
- Your major organs (liver, kidneys, bone marrow) are working well, based on blood tests.
- Your doctor expects you to live at least 12 more weeks.
- You do not have active HIV, hepatitis B, or hepatitis C, and you are not at immediate risk from the cancer or on blood thinners that cannot be paused.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for blood or tissue markers that can predict who benefits from immunotherapy given before surgery for non-small cell lung cancer. It may help doctors better choose treatment in the future.
This trial looks at whether certain cells in your lymph nodes (small immune glands) can predict how well PD-1 inhibitors (a type of immunotherapy) will work for your advanced or recurrent esophageal cancer. It aims to find a way to tailor treatment to each person.
This trial is testing a way to predict whether immunotherapy (a treatment that helps your immune system fight cancer) will completely eliminate esophageal cancer before surgery. By examining lymph nodes, they hope to tailor treatment more personally.
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
This study looks at genetic (DNA) information to find a marker that can help predict whether immunotherapy will work for lung cancer. If you’ve already received an immune checkpoint inhibitor, your tumor/genetic data may be analyzed to look for clues that guide treatment.
This trial studies how well immune checkpoint medicines (with or without chemotherapy) work for lung cancer, and looks for biomarkers—tests that may help predict who benefits. It may help you access a structured treatment plan and additional response testing.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.